Gemcitabine in Atypical Teratoid/Rhabdoid Tumors

Raw RNA-seq data belonging to the 'Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in Atypical Teratoid/Rhabdoid Tumors' manuscript.

VUMC-ATRT-03, VUMC-DIPG-10, VUMC-DIPG-11, VUMC-HGG-09, JHH-DIPG-01, HSJD-DIPG-07, and SU-pcGBM-2 neurospheres were treated with 5nM gemcitabine or DMSO as control. After 24h, cells were collected and processed as described previously. Sequencing, performed on an Illumina Nextseq 500 sequencer, data processing in the R2 platform (R2.amc.nl), and statistical analysis were also assessed as previously described.

本数据集为《吉西他滨通过靶向干扰非典型畸胎瘤/横纹肌样瘤（Atypical Teratoid/Rhabdoid Tumors, AT/RT）中SIRT1介导的p53抑制通路发挥治疗作用》研究手稿配套的原始RNA测序（RNA-seq）数据。
研究人员对VUMC-ATRT-03、VUMC-DIPG-10、VUMC-DIPG-11、VUMC-HGG-09、JHH-DIPG-01、HSJD-DIPG-07及SU-pcGBM-2神经球分别施加5nM浓度的吉西他滨处理，以二甲基亚砜（DMSO）作为空白对照。处理24小时后收集细胞，并按照此前已报道的方法完成样本制备与处理。测序实验采用因美纳（Illumina）Nextseq 500测序仪完成，后续数据处理依托R2数据分析平台（R2.amc.nl），统计分析流程亦参照此前已发表的方法执行。